Aligos Therapeutics Reports Q3 2026 Financial Results
Aligos Therapeutics released its Q3 2026 financial results, noting a narrowed operating loss and cash runway projections.
Stocks · News reference
Aligos Therapeutics Announces Acceptance Of Five Abstracts At American Association For Study Of Liver Disease's The Liver Meeting
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Aligos Therapeutics Announces Positive Data Presentations at AASLD The Liver Meeting 2026
Aligos Therapeutics reported positive data from five presentations at the AASLD's The Liver Meeting 2026, highlighting advancements in its pipeline for liver and viral diseases.
8-K filing — Aligos Therapeutics, Inc. (ALGS)
Filed: 2026-11-06 AccNo: 0001171843-26-007214 Size: 263 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
Aligos Therapeutics Initiates Dosing In Phase 1 Study Of ALG-170675, Investigational Next-Gen Antisense Oligonucleotide Being Evaluated For Functional Cure In Treatment Of Chronic HBV Infection
ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow rapid advancement into participants with chronic HBV infection in Q4 2026SOUTH